Authors


Jo Fearnhead-Wymbs

Latest:

Amplifying the Patient Voice

Jo Fearnhead-Wymbs discusses how and why amplifying the patient voice is driving change in the industry for the better.


Christine Phillips

Latest:

The Rise of EU Protectionism and M&A in Life Sciences

Christine Phillips looks at how an increase in protectionism across the EU member states with respect to foreign direct investment impacts the life sciences sector.


Ben Routley

Latest:

The Untapped Potential of Behavioral Science in Medical Affairs

Historically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.


Sam McClain

Latest:

AI + Social Media: The Intersection of 2 Contemporary Inventions Takes Physician Engagement to the Next Level

The two technologies are helping HCPs spread information and collect data in new ways.


Jim Reilly

Latest:

Mastering Patient Centricity’s Moving Parts: Innovators Share Real-World Examples

Agility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.


Thomas Shea

Latest:

From Endemic to POC: The Journey Pharma Marketers Need to Tread

The digital revolution has brought more efficient ways to reach and touch HCPs.



Sonja Rivera

Latest:

Merck Medical Affairs: An Enterprise-Wide Approach to Customer Intelligence

The importance of enabling customer intelligence at scale.


Kyle Forcier

Latest:

Optimized for Growth? Revenue Management in Pharma

According to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.


Gordon Cummins

Latest:

Refining, Rethinking, and Decentralizing Clinical Research

Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.


Katrine DiBona

Latest:

Healthy Planet, Healthy People: How Pharma Can Lead the Way

Reaching new heights in sustainability a win-win for industry.


Ricardo Rojo Cella, MD

Latest:

Janssen, Johns Hopkins Partner on Dermatology Ethnic Skin Program

Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.


Sy Chyi Yeoh

Latest:

Harnessing China’s Global Opportunity

Sy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.


Benedikt Porten

Latest:

Uncovering the Potential of Advanced Analytics in International Price Management

How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.


Duo Xu

Latest:

China’s 2022 NRDL Readout

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.


Emily Lowe, Michele Buenafe, and Kelli Boyle

Latest:

Digital-Deal Alignment: Considerations for Tech Agreements

The eight key areas biopharma manufacturers must stay on top of when planning and executing alliance agreements with prospective digital health partners.


Anthony Barron

Latest:

‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 Vaccines

In a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.


Jacob Braude

Latest:

Use Behavioral Science for Better Launch Success

Understanding of human behavior can aid in avoiding pitfalls during launch.



Mike Botta

Latest:

SPACs: From Fad to Fixture: COVID Sparks Greater Use of IPO Alternative

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?


Shawn W. Bates

Latest:

Accelerating Market Access with Data-Driven Payer Engagement

Using data visualizations to improve access to payers.


Cora Meese

Latest:

10 Market Access Trends to Watch for in 2023

As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.


Joe Baldini

Latest:

How AI is Revamping the Product Launch

New technology is allowing teams to analyze data at faster rates and make decisions much sooner than they previously could.


Andrea Pfeifer

Latest:

Are We Forgetting to Develop Vaccines for Diseases other than COVID?

It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.


C. Kuyler Doyle

Latest:

New Product Planning: The Function's Evolution in Pharma

With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.


Lorna Ewart, PhD, Chief Scientific Officer, Emulate, Brand Insights Contributor

Latest:

Protecting Human Health with Organ-on-a-Chip Technology

Organ-on-a-Chip technology has been proven to predict DILI with a higher rate of confidence than traditional in vitro methods and animals. Start protecting human health today.



Maria I. Florez

Latest:

Anticipating Digital Transformation of the Drug Development Workforce

The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.


Tahel Noy and Bill Woywod

Latest:

Market Segmentation with Novel Machine Learning

Merging strengths of traditional behavioral and attitudinal research, capability enables pharmaceutical field teams to prioritize resources, targets, and outreach strategies.


Larry King, PharmD

Latest:

Four for 2024: Predictions for the Future of Pharmacy Technology

Industry stakeholders must come together to make meaningful changes to reimbursement and establish comprehensive policies that support essential healthcare providers.